Multiple Myeloma Research Foundation (MMRF)
@themmrf.bsky.social
We are the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. themmrf.org
Tecvayli is approved for later line therapies in relapsed/refractory patients. However, studies at #IMS2025 are highlighting the impact bispecifics like Tecvayli can have for newly diagnosed patients. Efficacy results are still very early, but encouraging.
September 17, 2025 at 3:26 PM
Tecvayli is approved for later line therapies in relapsed/refractory patients. However, studies at #IMS2025 are highlighting the impact bispecifics like Tecvayli can have for newly diagnosed patients. Efficacy results are still very early, but encouraging.
Can we amend diagnostic criteria to help identify high risk smoldering patients? Dr. Sagar Lonial weighs in how circulating tumor cells could factor into these criteria #IMS2025
September 17, 2025 at 2:35 PM
Can we amend diagnostic criteria to help identify high risk smoldering patients? Dr. Sagar Lonial weighs in how circulating tumor cells could factor into these criteria #IMS2025
Having the right tests is important: they help your doctor confirm a diagnosis, assess the extent of your disease, & monitor progress once you start treatment. Download our Learn Your Labs booklet to better understand the blood tests used in myeloma care: themmrf.org/educational-...
July 16, 2025 at 3:41 PM
Having the right tests is important: they help your doctor confirm a diagnosis, assess the extent of your disease, & monitor progress once you start treatment. Download our Learn Your Labs booklet to better understand the blood tests used in myeloma care: themmrf.org/educational-...
⏰ URGENT: July 15 deadline approaching! #Myeloma patients are running out of options. The MMRF is the only organization solely dedicated to drug discovery and development for these patients. Your donation today will help extend lives. give.themmrf.org/campaign/687... #MMRF #CancerResearch
July 14, 2025 at 3:26 PM
⏰ URGENT: July 15 deadline approaching! #Myeloma patients are running out of options. The MMRF is the only organization solely dedicated to drug discovery and development for these patients. Your donation today will help extend lives. give.themmrf.org/campaign/687... #MMRF #CancerResearch
🚨 Calling early-career researchers! The 2025 MMRF Scholars Program is now accepting applications. $400K over 4 years for rising stars in myeloma research.
🧬 Apply by 9/30.
🔗 ow.ly/uz4P50WjfTv
#theMMRF #Myeloma #ResearchFunding #CancerResearch
🧬 Apply by 9/30.
🔗 ow.ly/uz4P50WjfTv
#theMMRF #Myeloma #ResearchFunding #CancerResearch
July 1, 2025 at 6:04 PM
🚨 Calling early-career researchers! The 2025 MMRF Scholars Program is now accepting applications. $400K over 4 years for rising stars in myeloma research.
🧬 Apply by 9/30.
🔗 ow.ly/uz4P50WjfTv
#theMMRF #Myeloma #ResearchFunding #CancerResearch
🧬 Apply by 9/30.
🔗 ow.ly/uz4P50WjfTv
#theMMRF #Myeloma #ResearchFunding #CancerResearch
This past weekend, Dr. Chuck Acharya, Associate Director of Translational Research at the MMRF, presented at #EHA2025:
🧬 Immunomodulatory Effects of Daratumumab-Based Therapy in FHRMM Patients (MyDRUG Trial)
📅 June 14
🧬 Immunomodulatory Effects of Daratumumab-Based Therapy in FHRMM Patients (MyDRUG Trial)
📅 June 14
June 16, 2025 at 8:03 PM
This past weekend, Dr. Chuck Acharya, Associate Director of Translational Research at the MMRF, presented at #EHA2025:
🧬 Immunomodulatory Effects of Daratumumab-Based Therapy in FHRMM Patients (MyDRUG Trial)
📅 June 14
🧬 Immunomodulatory Effects of Daratumumab-Based Therapy in FHRMM Patients (MyDRUG Trial)
📅 June 14
TOMORROW: Don't miss our Patient Livestream! Dr. Cindy Varga, PA Jordan Robinson, and a #myeloma patient will answer your questions & share real-life experiences with bispecific antibodies. Set a reminder: www.facebook.com/events/10294... #mmsm
June 10, 2025 at 10:54 PM
TOMORROW: Don't miss our Patient Livestream! Dr. Cindy Varga, PA Jordan Robinson, and a #myeloma patient will answer your questions & share real-life experiences with bispecific antibodies. Set a reminder: www.facebook.com/events/10294... #mmsm
Feeling overwhelmed by your #myeloma journey? You're not alone. Whether you’re smoldering, newly diagnosed, or relapsed/refractory, our mentors are here to offer guidance & share real-life experiences. Connect with a mentor: themmrf.org/support/myel...
June 9, 2025 at 10:05 PM
Feeling overwhelmed by your #myeloma journey? You're not alone. Whether you’re smoldering, newly diagnosed, or relapsed/refractory, our mentors are here to offer guidance & share real-life experiences. Connect with a mentor: themmrf.org/support/myel...
Wondering what bispecific antibody therapy is like? Join Dr. Cindy Varga, PA Jordan Robinson, & a #myeloma patient as they share real experiences & answer your questions.
📅 Live on Facebook!
👍 Mark "Interested" or "Going" on our event page: www.facebook.com/events/10294...
📅 Live on Facebook!
👍 Mark "Interested" or "Going" on our event page: www.facebook.com/events/10294...
June 5, 2025 at 9:14 PM
Wondering what bispecific antibody therapy is like? Join Dr. Cindy Varga, PA Jordan Robinson, & a #myeloma patient as they share real experiences & answer your questions.
📅 Live on Facebook!
👍 Mark "Interested" or "Going" on our event page: www.facebook.com/events/10294...
📅 Live on Facebook!
👍 Mark "Interested" or "Going" on our event page: www.facebook.com/events/10294...
Continuing the MRD discussion at #ASCO25 — Drs. Ben Derman, Luciano Costa, Rebecca Silbermann, and Neha Korde share thoughts MRD based treatment decisions for patients and the future of integrating MRD across clinics.
June 1, 2025 at 4:03 PM
Continuing the MRD discussion at #ASCO25 — Drs. Ben Derman, Luciano Costa, Rebecca Silbermann, and Neha Korde share thoughts MRD based treatment decisions for patients and the future of integrating MRD across clinics.
📚 NEW CME/CE for HCPs
Relapsed/refractory #myeloma remains a treatment challenge, but new options like CAR T-cell therapy & bispecifics are shifting the landscape.
Learn from leading experts in this FREE accredited activity. Claim your credit today: ce.paradigmmc.com/a/BXWSSW
Relapsed/refractory #myeloma remains a treatment challenge, but new options like CAR T-cell therapy & bispecifics are shifting the landscape.
Learn from leading experts in this FREE accredited activity. Claim your credit today: ce.paradigmmc.com/a/BXWSSW
May 29, 2025 at 9:28 PM
📚 NEW CME/CE for HCPs
Relapsed/refractory #myeloma remains a treatment challenge, but new options like CAR T-cell therapy & bispecifics are shifting the landscape.
Learn from leading experts in this FREE accredited activity. Claim your credit today: ce.paradigmmc.com/a/BXWSSW
Relapsed/refractory #myeloma remains a treatment challenge, but new options like CAR T-cell therapy & bispecifics are shifting the landscape.
Learn from leading experts in this FREE accredited activity. Claim your credit today: ce.paradigmmc.com/a/BXWSSW
It's not too late to sign up for our webinar happening TOMORROW at 12pm ET/9am PT! Join us to learn how bispecific antibodies work, the benefits they offer, potential side effects, & what patients can expect during treatment. Learn more & register here: event.webcasts.com/starthere.js...
May 27, 2025 at 10:03 PM
It's not too late to sign up for our webinar happening TOMORROW at 12pm ET/9am PT! Join us to learn how bispecific antibodies work, the benefits they offer, potential side effects, & what patients can expect during treatment. Learn more & register here: event.webcasts.com/starthere.js...
Horizon builds on our commitment to ensure that our research initiatives are representative of the real-world #myeloma patient population and inclusive of experiences that have not historically been reflected in research. Read our 2024 Donor Impact Report: themmrf.org/about/financ...
May 21, 2025 at 1:09 PM
Horizon builds on our commitment to ensure that our research initiatives are representative of the real-world #myeloma patient population and inclusive of experiences that have not historically been reflected in research. Read our 2024 Donor Impact Report: themmrf.org/about/financ...
Mark your calendars! You're invited to a 1-hour webinar where we'll talk about bispecific antibody therapy, an immunotherapy that helps the immune system recognize and destroy #myeloma cells. Don’t miss out—register now: event.webcasts.com/starthere.js...
May 16, 2025 at 6:20 PM
Mark your calendars! You're invited to a 1-hour webinar where we'll talk about bispecific antibody therapy, an immunotherapy that helps the immune system recognize and destroy #myeloma cells. Don’t miss out—register now: event.webcasts.com/starthere.js...
The MIF is the only mission-driven venture philanthropy fund focused on a cure for #myeloma. We invest in early-stage biotech companies developing innovative treatments that could be life-changing. Explore our portfolio: www.myelomainvestmentfund.org/portfolio/ #NationalCancerResearchMonth
May 15, 2025 at 9:10 PM
The MIF is the only mission-driven venture philanthropy fund focused on a cure for #myeloma. We invest in early-stage biotech companies developing innovative treatments that could be life-changing. Explore our portfolio: www.myelomainvestmentfund.org/portfolio/ #NationalCancerResearchMonth
Join us tomorrow for a live Q&A with Dr. Jodi Lipof & nurse practitioner Samantha Shenoy from @ucsfcancer.bsky.social, as they answer questions on CAR T-cell therapy. Plus, hear from a #myeloma patient about her experience with this treatment. Set a reminder here: www.facebook.com/events/12455...
May 13, 2025 at 8:35 PM
Join us tomorrow for a live Q&A with Dr. Jodi Lipof & nurse practitioner Samantha Shenoy from @ucsfcancer.bsky.social, as they answer questions on CAR T-cell therapy. Plus, hear from a #myeloma patient about her experience with this treatment. Set a reminder here: www.facebook.com/events/12455...
🔬 1,100+ #myeloma patients. 10+ years of data. The largest clinical-genomic study of its kind: the MMRF CoMMpass℠ Study. It's supported 100+ peer-reviewed papers, and countless abstracts & presentations worldwide. Learn more: themmrf.org/finding-a-cu... #NationalCancerResearchMonth
May 12, 2025 at 2:56 PM
🔬 1,100+ #myeloma patients. 10+ years of data. The largest clinical-genomic study of its kind: the MMRF CoMMpass℠ Study. It's supported 100+ peer-reviewed papers, and countless abstracts & presentations worldwide. Learn more: themmrf.org/finding-a-cu... #NationalCancerResearchMonth
The wait is almost over! Our MMRF Patient Summit, in partnership with @cityofhope.bsky.social, is happening TOMORROW. If you can’t make it in-person you can join virtually at 9am ET. Register now so you don’t miss out: event.webcasts.com/starthere.js...
May 9, 2025 at 6:42 PM
The wait is almost over! Our MMRF Patient Summit, in partnership with @cityofhope.bsky.social, is happening TOMORROW. If you can’t make it in-person you can join virtually at 9am ET. Register now so you don’t miss out: event.webcasts.com/starthere.js...
This #NationalNursesDay, we would like to thank nurses for the comfort & compassion they offer when we need it most. Special shoutout to our MMRF Patient Navigators, former oncology professionals supporting myeloma patients at every step. Drop a ❤️ to thank nurses everywhere!
May 6, 2025 at 5:36 PM
This #NationalNursesDay, we would like to thank nurses for the comfort & compassion they offer when we need it most. Special shoutout to our MMRF Patient Navigators, former oncology professionals supporting myeloma patients at every step. Drop a ❤️ to thank nurses everywhere!
🚨 Hurry! Secure your spot for our informative & interactive MMRF Patient Summit in partnership with @cityofhope.bsky.social. Discover the latest treatment strategies for newly diagnosed & relapsed/refractory #myeloma, managing symptoms & side effects, and more: event.webcasts.com/starthere.js...
May 5, 2025 at 3:51 PM
🚨 Hurry! Secure your spot for our informative & interactive MMRF Patient Summit in partnership with @cityofhope.bsky.social. Discover the latest treatment strategies for newly diagnosed & relapsed/refractory #myeloma, managing symptoms & side effects, and more: event.webcasts.com/starthere.js...
May is #NationalCancerResearchMonth 🔬 At the MMRF, we’re advancing new therapies, optimizing current treatments & improving care for every patient. Since 1998, the 5-year survival rate has risen from 34.6% to 61.1%. See how we’re getting closer to a cure: themmrf.org/finding-a-cu...
May 1, 2025 at 1:40 PM
May is #NationalCancerResearchMonth 🔬 At the MMRF, we’re advancing new therapies, optimizing current treatments & improving care for every patient. Since 1998, the 5-year survival rate has risen from 34.6% to 61.1%. See how we’re getting closer to a cure: themmrf.org/finding-a-cu...
📅 Mark your calendars! Don’t miss out on the MMRF Patient Summit in partnership with @cityofhope.bsky.social. This is your chance to engage with top #myeloma specialists, learn practical tips for managing symptoms & side effects, and more! Secure your spot: event.webcasts.com/starthere.js...
April 30, 2025 at 2:26 PM
📅 Mark your calendars! Don’t miss out on the MMRF Patient Summit in partnership with @cityofhope.bsky.social. This is your chance to engage with top #myeloma specialists, learn practical tips for managing symptoms & side effects, and more! Secure your spot: event.webcasts.com/starthere.js...